While CAR-iNKT directly reduced tumor burden through CAR-mediated cytotoxicity in a syngeneic murine model of B cell CD19+ lymphoma, complete anti-tumor efficacy required dendritic cell-mediated cross-priming of host CD8+ T cells (99). This evidence concerns the gene CD8A and neoplasm.